丁苯酞联合尤瑞克林治疗急性脑梗死效果及安全性的meta分析

doi:10.20047/j.issn1673-7210.2023.08.16

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (4145 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the efficacy and safety of Butylphthalide combined with Urinary Kallindinogenase in the treatment of acute cerebral infarction. Methods Randomized controlled trials of Butylphthalide combined with Urinary Kallindinogenase in the treatment of acute cerebral infarction were searched by computer from Cochrane Library, PubMed, Web of Science, Embase, CNKI, Wanfang Data, VIP, and SinoMed database. The retrieval period was from inception to January 2022. Data extraction, quality evaluation, and meta-analysis were performed by RevMan 5.4. Results A total of 11 articles were included, involving 1 088 patients. The results of meta-analysis showed that the total response rate of the combination group was higher than that of the monotherapy group (RR=1.20, 95%CI: 1.14 to 1.27, P＜0.000 01). The National Institutes of Health stroke scale (NIHSS) score of Butylphthalein Soft Capsules combination group was lower than that of monotherapy group (MD=-3.06, 95%CI:-3.73 to -2.39, P＜0.000 01), and the NIHSS score of Butylphthalein Injection combination group was lower than that of monotherapy group (MD=-5.70, 95%CI: -6.32 to -5.08, P＜0.000 01). There was no significant difference in the incidence of adverse reactions between the two groups (RR=1.50, 95%CI: 0.78 to 2.88, P=0.22). Funnel plot of total response rate showed no significant publication bias in the included literatures. Conclusion Butylphthalein combined with Urinary Kallindinogenase in the treatment of acute cerebral infarction is better than that of Urinary Kallindinogenase monotherapy. The two are comparable in terms of security.

Key words： Butylphthalide Urinary Kallindinogenase Acute cerebral infarction Meta-analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Zhongliang1 WANG Fei2 LIU Yang1 LI Zhe2 LIAN Shuai1 XUE Mengzhou1

Cite this article:

MA Zhongliang1 WANG Fei2 LIU Yang1 LI Zhe2 LIAN Shuai1 XUE Mengzhou1. Meta-analysis of the efficacy and safety of Butylphthalide combined with Urinary Kallindinogenase in the treatment of acute cerebral infarction[J]. 中国医药导报, 2023, 20(8): 74-78.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.08.16 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I8/74

[1] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组，彭斌.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9）：666-682.
[2] Zou W，Deng Y，Chen G，et al. Influence of butyphthalide combined with urinary kallikrein in ACI treatment on neuro-cytokines and vascular endothelial function and its clinical effect [J]. Int J Neurosci，2021：131，25-30.
[3] Xiang H，Zhang Q，Han Y，et al. Novel brain-targeting 3-n- butylphthalide prodrugs for ischemic stroke treatment [J]. J Control Release，2021：335，498-514.
[4] 贝筝，贝宁，龙发青，等.高压氧联合尤瑞克林在治疗老年急性缺血性脑卒中的临床有效性[J].中国老年学杂志，2021，41（17）：3643-3645.
[5] Ni J，Yao M，Wang L，et al. Human urinary kallidinogenase in acute ischemic stroke：A single-arm，multicenter，phase Ⅳ study（RESK study）[J]. CNS Neurosci Ther，2021：27， 1493-1503.
[6] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中国全科医学，2011，14（35）：4013-4017.
[7] 吴长鸿，刘斌.第四届全国脑血管病学术会议[J].中华医学信息导报，1996（6）：4.
[8] 朱维春，林彩云，邓春花.丁苯酞联合尤瑞克林对急性脑梗死患者炎症反应及肌力恢复的影响[J].黑龙江医药，2021，34（1）：51-53.
[9] 郭文敏，郭喜玲，和红霞.丁苯酞联合尤瑞克林对急性脑梗死患者颈动脉内膜中层厚度及血液流变学的影响[J].右江医学，2020，48（5）：363-366.
[10] 张明勤，吴涛.丁苯酞联合尤瑞克林对急性脑梗死患者神经功能及血浆内皮素-1和血清超敏C反应蛋白的影响[J].江苏预防医学，2020，31（1）：44-47.
[11] 甄诚，曹宾，刘明，等.丁苯酞和尤瑞克林联合治疗老年脑梗死进展期患者疗效及对患者凝血功能和神经功能缺损的影响[J].实用医院临床杂志，2020，17（2）：116-119.
[12] 黄运强，杨桂平，杨少明，等.尤瑞克林联合丁苯酞治疗急性脑梗死的疗效观察[J].广西医科大学学报，2019， 36（8）：1370-1373.
[13] 朱新岭，陈颖，杨君君，等.丁苯酞对急性脑梗死患者血管内皮功能的影响[J].中国慢性病预防与控制，2018， 26（6）：461-464.
[14] 罗德宏，林进光，郑精选.丁苯酞软胶囊联用尤瑞克林注射液治疗大面积脑梗死的临床疗效[J].北方药学，2017，14（4）：29-30.
[15] 庄清芬，苏为谦.尤瑞克林联合丁苯酞对72例急性脑梗死患者血管内皮功能及神经功能的影响[J].上海医药，2017，38（21）：16-18，37.
[16] 王东，张咏，邓可，等.尤瑞克林联合丁苯酞氯化钠注射液治疗急性进展型脑梗死的疗效观察[J].中南药学，2017，15（7）：989-992.
[17] 董珠，孙寄，郭娜，等.丁苯酞联合尤瑞克林治疗急性进展性脑梗死的疗效研究[J].医药与保健，2014（8）：73.
[18] 严拱榕.尤瑞克林与丁苯酞联合治疗急性脑梗死疗效观察：附80例分析[J].福建医药杂志，2011，33（3）：120- 121.
[19] 梁菊萍，杨旸，董继存.急性脑梗死患者流行病学调查及危险因素[J].中国老年学杂志，2021，41（12）：2484-2487.
[20] 郝雅文.急性脑梗死的治疗进展[J].天津药学，2021，33（4）：66-69.
[21] Cui P，McCullough LD，Hao J. Brain to periphery in acute ischemic stroke：Mechanisms and clinical significance [J]. Front Neuroendocrinol，2021：63，100932.
[22] 顾伟，朱正萍，陈玉兰，等.丁苯酞治疗急性缺血性脑卒中的效果及对血清因子的影响[J].中国医药导报，2022， 19（5）：86-88，92.
[23] 郑峥，陈兴泳，程琼，等.丁苯酞注射液治疗进展性脑卒中的疗效及安全性研究[J].中国全科医学，2016，19（3）：322-326.
[24] 付轶.尤瑞克林治疗急性脑梗死的临床有效性和安全性[J].临床合理用药杂志，2021，14（26）：39-41.
[25] Lin Z，Rao X，Zhang Z，et al. Economic evaluation of human urinary kallindinogenase for patients with acute ischemic stroke in China [J]. J Med Econ，2018：21，778- 783.